Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESH AL 2018 | The complications of treating elderly patients with AML

Gail Roboz • 4 May 2018
ESH AL 2018
Acute Myeloid Leukemia Leukemia Azacitidine Cytarabine Decitabine Venetoclax

The average age of people suffering from acute myeloid leukemia (AML) is around 60 to 70 years, and there are many issues surrounding the use of chemotherapy drugs in this population. In this interview, Gail Roboz, MD, from Weill Medical College of Cornell University, New York City, NY, highlights the challenges of AML treatment in the elderly, and some of the options that can be offered to patients in which high dose chemotherapy will not prove beneficial, or patients who have a low tolerance to intensive chemotherapy. This video was recorded at the 2018 European School of Hematology (ESH) Clinical Updates on Acute Leukemias, held in Budapest, Hungary.

More from Gail Roboz

New treatments in AML: FLT3 inhibitors & novel combinations
Gail Roboz et al. • 4 Sep 2023
2:01
Combining existing drugs for the creation of novel AML therapies
Gail Roboz • 4 May 2018
2:30
Increasing AML clinical trial participation rates
Gail Roboz • 4 May 2018
2:38
Managing relapse in AML: the role of MRD
Gail Roboz • 4 May 2018

Related Videos

1:40
The role of CPX-351 in the AML treatment landscape & insights into the AMLSG 30-18 trial
Felicitas Thol • 19 Apr 2024
3:21
Integrating genomics and MRD in transplant decision-making for patients with AML
Jurjen Versluis • 22 Apr 2024
4:19
Blinatumomab to achieve remission and consolidation with haploSCT for pediatric ALL
Alberto Olaya-Vargas • 15 Apr 2024
3:32
Improving CAR-T therapy for ALL & lymphoma: allogeneic products & reducing CRS/ICANS
Sridhar Chaganti • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals